16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies.

16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies.
复制标题

DOI：
--
复制
发表时间：
1982-05
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
通讯作者：
K. D. McElvany;J. Katzenellenbogen;K. Shafer;B. Siegel;S. G. Senderoff;M. Welch
K. D. McElvany;J. Katzenellenbogen;K. Shafer;B. Siegel;S. G. Senderoff;M. Welch
中科院分区：
其他
文献类型：
--
作者：
K. D. McElvany;J. Katzenellenbogen;K. Shafer;B. Siegel;S. G. Senderoff;M. Welch

文献摘要

被引文献

相似文献

An estrogen-receptor-binding radiopharmaceutical, 16 alpha-[77Br]bromoestradiol-17 beta, has been used successfully at high specific activity to image carcinogen-induced mammary tumors in rats and in preliminary studies to image breast tumors in patients. The biodistribution of the labeled estrogen in rats and its clearance in a monkey were used to estimate the radiation absorbed doses to a human resulting from administration of the radiopharmaceutical. Preliminary imaging studies in patients with mammary carcinoma show promising results and warrant further development of radiolabeled estrogens, particularly those carrying positron emitters that could permit positron emission tomography--for example Br-75 or F-18.